You are here

BLOOD SHUNT FOR ENZYMATIC MODIFICATION OF HEPARIN

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16541
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1991
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
195 Common Street
Belmont, MA 02178
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Trantolo, Debra J
 Principal Investigator
 (617) 484-3184
Business Contact
 1 R43 DK44385-01
Phone: () -
Research Institution
N/A
Abstract

THIS PHASE I GRANT REPRESENTS SUPPORT TO STUDY ENZYMATIC MODIFICATION OF HEPARIN. IN THIS RESEARCH, HEPARIN IS DESULFATED\A MANEUVER WHICH ALTERS THE RHEOLOGY AND ANTICOAGULANT PROPERTIES OF THE HEPARIN. REDUCTION IN SULFATION OF HEPARIN AS IT PASSES THROUGH RECIRCULATION SHUNTS DURING SURGERY WOULD ALLOW FOR RETURN OF HEPARIN TO THE PATIENT IN A FORM WHICH DOES NOT CONSTITUTE AN ANTICOAGULANT, THUS AVOIDING THE HEMORRHAGIC COMPLICATIONS WHICH SOMETIMES OCCUR IN HEPARINIZED EXTRACORPOREAL APPARATUS. IN PHASE I OF THE WORK, FEASIBILITY OF ENZYMATICALLY DESULFATING HEPARIN WILL BE CARRIED OUT. IF THE ANTICOAGULANT PROPERTIES OF THE MODIFIED HEPARIN ARE ALTERED, A SHUNT DEVICE TO ENZYMATICALLY DESULFATE THE HEPARIN WILL BE DEVELOPED. A SMALL COLUMN CONTAINING THE IMMOBILIZED ENZYMES WILL BE PLACED IN THE BYPASS APPARATUS, THROUGH WHICH BLOOD WILL FLOW. THE OUTLET OF THE DEVICE WILL LEAD BACK INTO THE PATIENT WITH A BLOOD PREPARATION WHICH IS OXYGENATED AND SAFE FROM THE STANDPOINT OF HAVING PROPERTIES WHICH COULD INDUCE HEMORRHAGE.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government